Robert Potashnick Power - 24 Aug 2026 Form 4 Insider Report for Envoy Medical, Inc. (COCH)

Reporting relationship: CAO & VP of Finance
Issuer ticker: COCH
Reported as of: 24 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Aug 2026, 17:08:23 UTC
Prior SEC filing: 17 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Andrew Nick as Attorney-in-Fact for Robert Potashnick pursuant to Power of Attorney previously filed.

Key filing fact

Robert Potashnick Power filed Form 4 for Envoy Medical, Inc. (COCH) on 26 Aug 2026.

Key facts

This page summarizes Robert Potashnick Power's Form 4 filing for Envoy Medical, Inc. (COCH).
1 reported transaction and 4 derivative rows are listed below.
Accepted by SEC: 26 Aug 2026, 17:08.

Change

Previous filing in this sequence was filed on 17 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001939454 Primary reporting owner

Potashnick Robert

Relationship: CAO & VP of Finance
Address: C/O 4875 WHITE BEAR PARKWAY, WHITE BEAR LAKE
Signature: /s/ Andrew Nick as Attorney-in-Fact for Robert Potashnick pursuant to Power of Attorney previously filed.
Signature date: 26 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

COCH holding

Class A Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 212,500
Date: 24 Aug 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

COCH transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +250,000
Change %
Price: $0.000000^*
Shares after: 250,000
Date: 24 Aug 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 250,000
Exercise price: $0.7460
Footnotes: F2

COCH holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 15,000
Date: 24 Aug 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 15,000
Exercise price: $0.5300
Footnotes: F1

COCH holding Derivative

Warrant (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 127,500
Date: 24 Aug 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 127,500
Exercise price: $0.4000
Footnotes: F3, F4

COCH holding Derivative

Warrant (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 212,500
Date: 24 Aug 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 212,500
Exercise price: $0.4000
Footnotes: F3, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Options to purchase 3,750 shares vest on 2/5/2027, and 11,250 shares vest pro rata on the 5th of each month thereafter for 36 consecutive months.

Footnote F2

Options to purchase 62,500 shares vest on 8/24/2027, and 187,500 shares vest pro rata on the 24th of each month thereafter for 36 consecutive months.

Footnote F3

Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants.

Footnote F4

The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device.

Footnote F5

The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device.